185 related articles for article (PubMed ID: 30820474)
1.
Hernandez R; Walker KL; Grudzinski JJ; Aluicio-Sarduy E; Patel R; Zahm CD; Pinchuk AN; Massey CF; Bitton AN; Brown RJ; Sondel PM; Morris ZS; Engle JW; Capitini CM; Weichert JP
Commun Biol; 2019; 2():79. PubMed ID: 30820474
[TBL] [Abstract][Full Text] [Related]
2.
Hernandez R; Grudzinski JJ; Aluicio-Sarduy E; Massey CF; Pinchuk AN; Bitton AN; Patel R; Zhang R; Rao AV; Iyer G; Engle JW; Weichert JP
J Nucl Med; 2020 Aug; 61(8):1187-1194. PubMed ID: 31862799
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Characterization of
Grudzinski JJ; Hernandez R; Marsh I; Patel RB; Aluicio-Sarduy E; Engle J; Morris Z; Bednarz B; Weichert J
J Nucl Med; 2019 Nov; 60(11):1622-1628. PubMed ID: 30954941
[TBL] [Abstract][Full Text] [Related]
4. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
7. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
8. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
[TBL] [Abstract][Full Text] [Related]
9. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
10. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
Magee K; Marsh IR; Turek MM; Grudzinski J; Aluicio-Sarduy E; Engle JW; Kurzman ID; Zuleger CL; Oseid EA; Jaskowiak C; Albertini MR; Esbona K; Bednarz B; Sondel PM; Weichert JP; Morris ZS; Hernandez R; Vail DM
PLoS One; 2021; 16(8):e0255798. PubMed ID: 34383787
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs.
Zhang RR; Choi C; Brunnquell CL; Hernandez R; Pinchuk AN; Grudzinski JG; Clark PA; McMillan AB; Audhya A; Jeffrey J; Kuo JS; Weichert JP
Invest Radiol; 2022 Oct; 57(10):655-663. PubMed ID: 36069439
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
Schmidberger H; Buchsbaum DJ; Blazar BR; Everson P; Vallera DA
Cancer Res; 1991 Apr; 51(7):1883-90. PubMed ID: 2004371
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
15. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
18.
Ferreira CA; Ehlerding EB; Rosenkrans ZT; Jiang D; Sun T; Aluicio-Sarduy E; Engle JW; Ni D; Cai W
Mol Pharm; 2020 May; 17(5):1697-1705. PubMed ID: 32202792
[TBL] [Abstract][Full Text] [Related]
19. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
20. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
